undamentalytics Newsletter
Sign in

Zevra Therapeutics, Inc. insider trading

Every open-market purchase and sale by Zevra Therapeutics, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.

Insider purchases, 5 years $0 0 trades by 0 insiders Insider sales, 5 years $2.7M 14 trades by 6 insiders 3 months later: median +11.9% (+7.5% vs S&P 500)

No insider has bought shares on the open market in five years.

Insider purchase Insider sale Marker size reflects trade value. Weekly closes adjusted for splits; may be delayed.
DateInsiderTrade SharesPriceValue 1M after 3M after 6M after

From insiders' Form 4 filings with the SEC: open-market purchases and sales only (awards, option exercises and shares withheld for tax are excluded), combined to one line per insider per day. "Plan" marks trades the filing says were made under a pre-set Rule 10b5-1 trading plan, which are scheduled in advance. Price changes run from the close on the trade date; hover a figure for the change relative to the S&P 500. Past moves don't predict future ones.

Does following Zevra Therapeutics, Inc.’s insiders pay?

From March 30, 2016 to August 12, 2026, 16 insiders reported 44 open-market purchases and 1 sale not made under a pre-set plan in Zevra Therapeutics, Inc. Twelve months after each purchase was reported, the shares were −17.6% against the S&P 500 on average (median −29.8%), over 26 purchases with a full year of prices; 39% beat the index. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on March 31, 2016 into $653 by November 2, 2026, −22.8% a year. It held shares 73% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $26,906 (+9.8% a year), and held throughout $43,544 (+14.9%).

$0$20.0k$40.0k 201620182020202220242026 $43.5k$26.9k$653
Copying Zevra Therapeutics, Inc.'s insidersS&P 500, same days investedS&P 500, held throughout $10,000 copying every open-market purchase by Zevra Therapeutics, Inc.'s insiders from March 31, 2016, before costs and taxes, marked weekly. Uninvested money earns the Treasury bill rate; the portfolio held shares 73% of the time.
InsiderRolePurchases12 months after their purchasesBeat the S&P 500Sales12 months after their salesLatest report
Mickle Travis C President & CEO 10 −52.5% (5) 0% 0 — May 25, 2022
Cohen Daniel L EVP, Govt. & Public Relations 7 −67.4% (2) 0% 0 — May 17, 2018
Bode John B Director 5 +7.0% (5) 60% 0 — August 20, 2025
Pascoe Richard W Chief Executive Officer 4 −18.8% (3) 33% 0 — March 13, 2023
Anderson Thomas Director 2 +38.2% (2) 100% 0 — July 16, 2024
Clifton R. Laduane CFO & Treasurer 2 +11.7% (2) 50% 0 — July 17, 2024
Delaware Street Capital Master Fund, L.P. 10% owner 2 — — 0 — October 9, 2018
Johnson Gordon K Chief Business Officer 2 — — 0 — October 12, 2018
Mickle Christal M M VP Prod Dev 2 −70.8% (2) 0% 0 — August 18, 2016
Plooster Matthew R Director 2 +1.0% (1) 100% 0 — March 13, 2023
Tierney David S Director 2 −31.8% (1) 0% 0 — March 13, 2023
Braun Samuel J 10% owner 1 −52.7% (1) 0% 0 — May 17, 2021
Dsc Advisors, L.L.C. 10% owner 1 — — 0 — August 1, 2018
Favorito Tamara A Director 1 +41.3% (1) 100% 0 — September 16, 2025
Shih Alvin Director 1 +46.3% (1) 100% 0 — September 15, 2025
Watton Corey Michael Director 0 — — 1 — August 12, 2026

Moves are the shares’ return including dividends minus the S&P 500’s, from the close on the first trading day after each report; the number of trades with a finished 12-month window is in brackets. Green means the trade went the insider’s way (a purchase ahead of the index, a sale followed by the shares trailing it). A trade reported both by a director or officer and by a fund or company they are linked to counts once here, under the person. Purchases count only where the share price actually traded was at least $5. These figures describe what the shares did, not why anyone traded. Insiders across all companies.

When several insiders traded Zevra Therapeutics, Inc.

Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Zevra Therapeutics, Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 6 buying crowds with six months of prices, it averaged −25.5% against the index. One company's history is too short to judge by; the test across every company is the better guide.

MonthCrowd3 months on, vs S&P 5006 months12 months
September 30, 20253 buying−10.8%0.0%−8.9%
July 31, 20243 buying+21.3%+10.8%+57.3%
March 31, 20233 buying−16.4%−19.3%−37.3%
December 31, 20213 buying−36.3%−27.4%−29.5%
June 30, 20212 buying−30.4%−41.5%−54.6%
March 31, 20162 buying−72.6%−75.7%−83.9%

Colours show whether the crowd was right: green when buyers were followed by a rise above the index, or sellers by a fall below it. Total returns from the month end; past patterns are not a forecast.

← Back to Zevra Therapeutics, Inc. · Funds · Politicians